Conditionally replicating oncolytic adenoviral vector expressing arresten and tumor necrosis factor-related apoptosis-inducing ligand experimentally suppresses lung carcinoma progression

Li,Shudong; Qi,Zongli; Li,Huijin; Hu,Jun; Wang,Dongyang; Wang,Xin; Feng,Zhenzhen

doi:10.3892/mmr.2015.3624

Conditionally replicating oncolytic adenoviral vector expressing arresten and tumor necrosis factor-related apoptosis-inducing ligand experimentally suppresses lung carcinoma progression

Authors:
- Shudong Li
- Zongli Qi
- Huijin Li
- Jun Hu
- Dongyang Wang
- Xin Wang
- Zhenzhen Feng
View Affiliations

Affiliations: Department of Thoracic Surgery, Shaanxi Provincial People's Hospital, Third Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710068, P.R. China, Laboratory Center, Shaanxi Provincial People's Hospital, Third Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710068, P.R. China, Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi 710119, P.R. China
Published online on: April 16, 2015 https://doi.org/10.3892/mmr.2015.3624
Pages: 2068-2074

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Current methods of treatment for lung carcinoma are ineffective for the majority of patients. Conditionally replicating adenoviruses (CRAds) represent a potential novel treatment for a number of neoplastic diseases, including lung carcinoma. The present study aimed to investigate the synergistic mechanisms underlying the anti‑angiogenesis gene, arresten, and the apoptosis‑inducing gene, tumor necrosis factor‑related apoptosis‑inducing ligand (TRAIL), in order to evaluate their therapeutic potential in lung cancer. The two genes were expressed by CRAd, which was confirmed using reverse transcription‑polymerase chain reaction and western blotting. In vitro analyses demonstrated that CRAd adenoviruses are capable of selectively inhibiting A549 lung cancer cell growth and replication but not in that of healthy cells. In vivo analyses demonstrated that the infection of A549 cell lines using CRAd armed with the two genes (CRAd‑arresten‑TRAIL) enhanced the tumor inhibition, compared with cells infected with CRAd‑arresten, CRAd‑TRAIL or CRAd, and with the control group. CRAd‑arresten‑TRAIL may therefore be useful in the treatment of lung cancer.

View Figures

View References

1	Chen W, Zheng R, Zhang S, Zou X, Zhao P and He J: Lung cancer incidence and mortality in China, 2009. Thoracic Cancer. 4:102–108. 2013. View Article : Google Scholar
2	Parkin DM, Bray FI and Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl 8): S4–S66. 2001. View Article : Google Scholar : PubMed/NCBI
3	Ghosh SS, Gopinath P and Ramesh A: Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol. 133:9–29. 2006. View Article : Google Scholar : PubMed/NCBI
4	Rein DT, Breidenbach M and Curiel DT: Current developments in adenovirus-based cancer gene therapy. Future Oncol. 2:137–143. 2006. View Article : Google Scholar : PubMed/NCBI
5	Jounaidi Y, Doloff JC and Waxman DJ: Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets. 7:285–301. 2007. View Article : Google Scholar : PubMed/NCBI
6	Bilsland AE, Merron A, Vassaux G and Keith WN: Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses. Cancer Res. 67:1299–1307. 2007. View Article : Google Scholar : PubMed/NCBI
7	Lanson NA Jr, Friedlander PL, Schwarzenberger P, et al: Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res. 63:7936–7941. 2003.PubMed/NCBI
8	Haviv YS: A simplified in vitro ligation approach to clone an E1B55k-deleted double-targeted conditionally-replicative adenovirus. Virol J. 6:182009. View Article : Google Scholar : PubMed/NCBI
9	Chen MJ, Green NK, Reynolds GM, et al: Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther. 11:1126–1136. 2004. View Article : Google Scholar : PubMed/NCBI
10	Graat HC, van Beusechem VM, Schagen FH, et al: Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. Mol Cancer. 7:92008. View Article : Google Scholar : PubMed/NCBI
11	Lamfers M, Idema S, Bosscher L, et al: Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Clin Cancer Res. 13:7451–7458. 2007. View Article : Google Scholar : PubMed/NCBI
12	Ries S and Korn WM: ONYX-015: mechanism of action and clinical potential of replication-selective adenovirus. Br J Cancer. 86:5–11. 2002. View Article : Google Scholar : PubMed/NCBI
13	Heise C and Kirn DH: Replication-selective adenoviruses as oncolytic agents. J Clin Invest. 105:847–851. 2000. View Article : Google Scholar : PubMed/NCBI
14	Brown CB and Bell JC: Oncolytic viruses: A new weapon to fight cancer. J Med Imag Rad Sci. 39:115–127. 2008. View Article : Google Scholar
15	Vähä-Koskela MJ, Heikkilä JE and Hinkkanen AE: Oncolytic viruses in cancer therapy. Cancer Lett. 254:178–216. 2007. View Article : Google Scholar : PubMed/NCBI
16	He XP, Su CQ, Wang XH, et al: E1B-55kDa-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Lett. 285:89–98. 2009. View Article : Google Scholar : PubMed/NCBI
17	Fan JK, Xiao T, Gu JF, et al: Increased suppression of oncolytic adenovirus carrying mutant k5 on colorectal tumor. Biochemical Biophys Res Commun. 374:198–203. 2008. View Article : Google Scholar
18	Sudhakar A, Nyberg P, Keshamouni VG, et al: Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest. 115:2801–2810. 2005. View Article : Google Scholar : PubMed/NCBI
19	Chai L, Liu S, Mao Q, Wang D, Li X, Zheng X and Xia H: A novel conditionally replicating adenoviral vector with dual expression of IL-24 and arresten inserted in E1 and the region between E4 and fiber for improved melanoma therapy. Cancer Gene Ther. 19:247–254. 2012. View Article : Google Scholar
20	National Research Council of The National Academies: Guide for the care and use of laboratory animals. 8th edition. The National Academies Press; Washington, DC: 2011
21	Li X, Mao QW, Wang DY, Zhang WF and Xia HB: A fiber chimeric CRAd vector Ad5/11-D24 double-armed with TRAIL and arresten for enhanced glioblastoma. Hum Gene Ther. 23:589–596. 2012. View Article : Google Scholar
22	Kim DR, Park MY, Lee CS, et al: Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. Cancer Gene Ther. 18:467–477. 2011. View Article : Google Scholar : PubMed/NCBI
23	Zhang H, Sui A, Wang Z, Liu S and Yao R: Adenovirus-mediated TRAIL expression and downregulation of Bcl-2 expression suppresses non-small cell lung cancer growth in vitro and in vivo. Int J Mol Med. 30:358–364. 2012.PubMed/NCBI
24	Holoch PA and Griffith TS: TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol. 625:63–72. 2009. View Article : Google Scholar : PubMed/NCBI
25	Kim CY, Park SH, Jeong M, et al: Preclinical studies for pharmacokinetics and biodistribution of Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy. Exp Mol Med. 43:580–586. 2011. View Article : Google Scholar : PubMed/NCBI
26	Colorado PC, Torre A, Kamphaus G, et al: Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60:2520–2526. 2000.PubMed/NCBI
27	Aikio M, Alahuhta I, Nurmenniemi S, et al: Arresten, a collagen-derived angiogenesis inhibitor, suppresses invasion of squamous cell carcinoma. PLoS One. 7:e510442012. View Article : Google Scholar : PubMed/NCBI
28	Boosani CS, Nalabothula N, Munugalavadla V, et al: FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IVC1. Invest Ophthalmol Vis Sci. 50:4567–4575. 2009. View Article : Google Scholar : PubMed/NCBI
29	Assadian S, El-Assaad W, Wang XQ, et al: p53 inhibits angiogenesis by inducing the production of Arresten. Cancer Res. 72:1270–1279. 2012. View Article : Google Scholar : PubMed/NCBI